缺血性脑血管病抗血小板治疗的现状与进展被引量：1

The Status and Progress of Antiplatelet Therapy In Ischemic Cerebrovascular Disease

下载PDF

导出

摘要抗血小板治疗是缺血性脑卒中治疗的重要手段之一。阿司匹林在卒中的二级预防和急性期治疗中的疗效已得到证实。潘生丁抑制血小板作用持续时间较短且呈剂量依赖性。氯吡格雷是二磷酸腺苷(ADP)受体拮抗剂,是合适的阿司匹林替代药。GPⅡb/Ⅲa受体拮抗剂静脉注射有效而口服的临床结果欠佳。抗血小板药物联合应用有利于提高疗效增加安全性。 Antipatelet therapy is one of the most inportant approachs in the treatment of ischemic stroke. The efficacy of Asprin has been confirmed in brain stroke not only in its treatment of acute stage, but also in its second-level prevention; Pensantin＇s antiplatelet efficacy lasts for a short time, and time and dosage dependant. Clopidogel is a adennosine diphosphate receptor antagonist which is a suitable replacement of asprins. The efficacy of glycoprotein Ⅱ b/Ⅲ a receptor inhibitor used in vein is clear, but its clinic outcome of oral medicine works below the mark. The usage of antiplatelet drug in combination is helpful in promoting the therapeutic efficacy and safty.

作者张强

机构地区天津河西医院神经内科

出处《医学综述》 2006年第9期536-538,共3页 Medical Recapitulate

关键词缺血性脑血管病抗血小板治疗 Ischemic cerebrovascular disease Antiplatelet Therapy

分类号 R743.3 [医药卫生—神经病学与精神病学]

引文网络
相关文献

参考文献18

1刘译霖,贺石林,李家增．血栓性疾病的诊断与治疗[M]．北京：人民卫生出版社,2000．42-43．
2Reiner AP, Kumer PN, Schwartz SM, et al. Genetic variants of platelet glycoprotein receptors and risk of stroke in young women[J]. Stroke,2000,31 (6):1628-1633.
3Llinas R, Caplan LR. Evidence-based treatment of patients with ischemic cerebrovascular disease[J]. Neurol Clin, 2001,19( 1 ) : 79-105.
4Chen ZM, Sandercock P, Pan HC, et al. Indications for early aspirin use in acute ischemic stroke: A combined analysis of 40000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups[J]. Stroke,2000,31 (5) : 1240-1249.
5Diener HC. Aspirin in the prevention of strokes[J]. Biomed Pharmacother, 1999,53(2) :309-311.
6Farres MT, Grabeawoger F, Gross CE, et al. Antithrombotic Trialists Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death myocardial infarction, and stroke in high risk patlents[J]. BMJ, 2002,324( 1 ) :71-86.
7Manns-JM, Brenna KJ,Colman RW,et al. Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphediester ases[J]. Thremb Haemost, 2002,87 (4) : 873-879.
8Patrono C, CoRer B, Dalen JE, et al. Platelet-active drugs: the relationships among dose, and side effects[J]. Chest,2001,119( 1 ) : 39s-63s.
9Paciaroni M, Bogousslavsky J. Clopidogrel for cerebrovascular prevention[J] . Cerebrovasc Dis, 1999,9(2) :253-260.
10Hankey GJ, Sudlow CL, Dunbabin DW. Thienopyridinea or aspirin to prenvent stroke and other serious vascular events in patients at high risk of vasucular disease? A systematic review of evidence from randomized trials[J]. Stoke, 2000,31(6) : 1799-1784.